<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0236217</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6077</journal-id>
<journal-id journal-id-type="nlm-ta">Neuropharmacology</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuropharmacology</journal-id>
<journal-title-group>
<journal-title>Neuropharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0028-3908</issn>
<issn pub-type="epub">1873-7064</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26944732</article-id>
<article-id pub-id-type="pmc">5010529</article-id>
<article-id pub-id-type="doi">10.1016/j.neuropharm.2016.03.001</article-id>
<article-id pub-id-type="manuscript">NIHMS773157</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Elevated kynurenine pathway metabolism during neurodevelopment: Implications for brain and behavior</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Notarangelo</surname>
<given-names>Francesca M.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pocivavsek</surname>
<given-names>Ana</given-names>
</name>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<aff id="A1">Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA</aff>
</contrib-group>
<author-notes>
<corresp id="FN1"><label>*</label>Corresponding author. Maryland Psychiatric Research Center, P.O. Box 21247, Baltimore, MD 21228, USA. <email>apocivavsek@mprc.umaryland.edu</email> (A. Pocivavsek)</corresp>
<fn fn-type="COI-statement" id="FN2">
<p>
<bold>Conflicts of interest</bold>
</p>
<p>The authors declare no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>23</day>
<month>4</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>2</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>1</month>
<year>2018</year>
</pub-date>
<volume>112</volume>
<issue>Pt B</issue>
<fpage>275</fpage>
<lpage>285</lpage>
<!--elocation-id from pubmed: 10.1016/j.neuropharm.2016.03.001-->
<abstract>
<p id="P1">The kynurenine pathway (KP) of tryptophan degradation contains several neuroactive metabolites that may influence brain function in health and disease. Mounting focus has been dedicated to investigating the role of these metabolites during neurodevelopment and elucidating their involvement in the pathophysiology of psychiatric disorders with a developmental component, such as schizophrenia. In this review, we describe the changes in KP metabolism in the brain from gestation until adulthood and illustrate how environmental and genetic factors affect the KP during development. With a particular focus on kynurenic acid, the antagonist of α7 nicotinic acetylcholine (α7nACh) and N-methyl-D-aspartate (NMDA) receptors, both implicated in modulating brain development, we review animal models designed to ascertain the role of perinatal KP elevation on long-lasting biochemical, neuropathological, and behavioral deficits later in life. We present new data demonstrating that combining perinatal choline-supplementation, to potentially increase activation of α7nACh receptors during development, with embryonic kynurenine manipulation is effective in attenuating cognitive impairments in adult rat offspring. With these findings in mind, we conclude the review by discussing the advancement of therapeutic interventions that would target not only symptoms, but potentially the root cause of central nervous system diseases that manifest from a perinatal KP insult.</p>
</abstract>
<kwd-group>
<kwd>Kynurenic acid</kwd>
<kwd>Schizophrenia</kwd>
<kwd>Cognition</kwd>
<kwd>Alpha 7 nicotinic receptor</kwd>
<kwd>Choline</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>